知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

25 records (took 0.049 seconds)

    SPIROKETAL DERIVATIVES AND USE THEREOF AS DIABETIC MEDICINE
    1.
    发明申请
    SPIROKETAL DERIVATIVES AND USE THEREOF AS DIABETIC MEDICINE 有权
    SPIROKETAL衍生物及其作为糖尿病药物的用途

    公开(公告)号：US20090030006A1

    公开(公告)日：2009-01-29

    申请号：US11815074

    申请日：2006-01-27

    Applicant: Takamitsu Kobayashi ,  Tsutomu Sato ,  Masahiro Nishimoto

    Inventor： Takamitsu Kobayashi ,  Tsutomu Sato ,  Masahiro Nishimoto

    IPC: A61K31/352 ,  A61P3/10 ,  C07D493/10 ,  A61K31/381 ,  A61K31/4433 ,  A61K31/498 ,  A61K31/404 ,  A61K31/4155 ,  C07D495/20 ,  C07D491/20

    CPC classification number: C07D311/96 ,  C07D491/153 ,  C07D493/10 ,  C07H19/01

    Abstract: The present invention provides a compound of Formula (I): wherein R1, R2, R3 and R4 are each independently selected from a hydrogen atom, an optionally substituted C1-C6 alkyl group, an optionally substituted C7-C14 aralkyl group and —C(═O)Rx; Rx represents an optionally substituted C1-C6 alkyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted C1-C6 alkoxy group or —NReRf; Ar1 represents an optionally substituted aromatic carbocyclic ring or an optionally mono-substituted aromatic heterocyclic ring; Q represents —(CH2)m-(L)p- or -(L)p-(CH2)m—; m represents an integer selected from 0 to 2, n represents an integer selected from 1 and 2, and p represents an integer selected from 0 and 1; L represents —O—, —S— or —NR5—; and A represents an optionally substituted aryl group or an optionally substituted heteroaryl group, a prodrug thereof and a pharmaceutically acceptable salt thereof, as well as a pharmaceutical preparation or pharmaceutical composition comprising such a compound.

    Abstract translation: 本发明提供式（I）的化合物：其中R 1，R 2，R 3和R 4各自独立地选自氢原子，任选取代的C 1 -C 6烷基，任选取代的C 7 -C 14芳烷基和-C（ -O）Rx; Rx表示任选取代的C 1 -C 6烷基，任选取代的芳基，任选取代的杂芳基，任选取代的C 1 -C 6烷氧基或-NRrf; Ar 1表示任选取代的芳族碳环或任选单取代的芳族杂环; Q表示 - （CH 2）m - （L）p-或 - （L）p-（CH 2）m - ; m表示选自0至2的整数，n表示选自1和2的整数，p表示选自0和1的整数; L表示-O - ， - S-或-NR5-; A表示任选取代的芳基或任选取代的杂芳基，其前药及其药学上可接受的盐，以及包含这种化合物的药物制剂或药物组合物。

    Spiroketal derivatives and use thereof as diabetic medicine
    2.
    发明授权
    Spiroketal derivatives and use thereof as diabetic medicine 有权
    螺缩酮衍生物及其作为糖尿病药物的用途

    公开(公告)号：US07767651B2

    公开(公告)日：2010-08-03

    申请号：US11815074

    申请日：2006-01-27

    Applicant: Takamitsu Kobayashi ,  Tsutomu Sato ,  Masahiro Nishimoto

    Inventor： Takamitsu Kobayashi ,  Tsutomu Sato ,  Masahiro Nishimoto

    IPC: A01N43/04 ,  C07H1/00 ,  C07H3/00 ,  C08B37/00

    CPC classification number: C07D311/96 ,  C07D491/153 ,  C07D493/10 ,  C07H19/01

    Abstract: The present invention provides a compound of Formula (I): wherein R1, R2, R3 and R4 are each independently selected from a hydrogen atom, an optionally substituted C1-C6 alkyl group, an optionally substituted C7-C14 aralkyl group and —C(═O)Rx; Rx represents an optionally substituted C1-C6 alkyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted C1-C6 alkoxy group or —NReRf; Ar1 represents an optionally substituted aromatic carbocyclic ring or an optionally mono-substituted aromatic heterocyclic ring; Q represents —(CH2)m-(L)p- or -(L)p-(CH2)m—; m represents an integer selected from 0 to 2, n represents an integer selected from 1 and 2, and p represents an integer selected from 0 and 1; L represents —O—, —S— or —NR5—; and A represents an optionally substituted aryl group or an optionally substituted heteroaryl group, a prodrug thereof and a pharmaceutically acceptable salt thereof, as well as a pharmaceutical preparation or pharmaceutical composition comprising such a compound.

    Abstract translation: 本发明提供式（I）的化合物：其中R 1，R 2，R 3和R 4各自独立地选自氢原子，任选取代的C 1 -C 6烷基，任选取代的C 7 -C 14芳烷基和-C（ ΟO）Rx; Rx表示任选取代的C 1 -C 6烷基，任选取代的芳基，任选取代的杂芳基，任选取代的C 1 -C 6烷氧基或-NRrf; Ar 1表示任选取代的芳族碳环或任选单取代的芳族杂环; Q表示 - （CH 2）m - （L）p-或 - （L）p-（CH 2）m - ; m表示选自0至2的整数，n表示选自1和2的整数，p表示选自0和1的整数; L表示-O - ， - S-或-NR5-; A表示任选取代的芳基或任选取代的杂芳基，其前药及其药学上可接受的盐，以及包含这种化合物的药物制剂或药物组合物。

    Glucitol derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes
    6.
    发明授权
    Glucitol derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes 失效
    葡萄糖醇衍生物，其前药及其盐，以及含有糖尿病的治疗剂

    公开(公告)号：US07943748B2

    公开(公告)日：2011-05-17

    申请号：US11658765

    申请日：2005-07-27

    Applicant: Hiroharu Matsuoka ,  Tsutomu Sato ,  Masahiro Nishimoto ,  Yasuhara Kato ,  Masahiro Sakaitani ,  Sang-Hak Lee

    Inventor： Hiroharu Matsuoka ,  Tsutomu Sato ,  Masahiro Nishimoto ,  Yasuhara Kato ,  Masahiro Sakaitani ,  Sang-Hak Lee

    IPC: C07H1/00 ,  A01N43/04 ,  A61K31/70

    CPC classification number: C07D409/10

    Abstract: The invention provides a glucitol derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): wherein m is an integer selected among 1-3; R1 to R4 each independently is optionally substituted alkyl, etc.; Ar1 is optionally substituted naphthyl; and A is optionally substituted heteroaryl, a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, and the like each containing the compound.

    Abstract translation: 本发明提供了具有降低血糖水平并且具有药物所需的优选性能如持久药物活性的功能的葡糖醇衍生物; 以及用于预防或治疗高血糖疾病如糖尿病，糖尿病并发症和肥胖症的药物组合物。 该衍生物是由式（I）表示的化合物：其中m是选自1-3的整数; R1至R4各自独立地为任选取代的烷基等; Ar1是任选取代的萘基; 和A是任选取代的杂芳基，该化合物的前药或其药学上可接受的盐。 还提供了含有化合物的药物，药物组合物等。

    Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes
    7.
    发明申请
    Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes 有权
    新型环己烷衍生物，其前体药物及其盐，以及含有糖尿病的治疗剂

    公开(公告)号：US20080318874A1

    公开(公告)日：2008-12-25

    申请号：US11658400

    申请日：2005-07-26

    Applicant: Hiroharu Matsuoka ,  Tsutomu Sato ,  Masahiro Nishimoto ,  Nobuo Shimma

    Inventor： Hiroharu Matsuoka ,  Tsutomu Sato ,  Masahiro Nishimoto ,  Nobuo Shimma

    IPC: A61K31/7028 ,  C07G3/00 ,  C07D209/04 ,  A61K31/403 ,  A61K31/05 ,  A61P3/10

    CPC classification number: C07D333/32 ,  C07C35/14 ,  C07C35/48 ,  C07C43/23 ,  C07C43/253 ,  C07C69/94 ,  C07C217/58 ,  C07C235/46 ,  C07C255/54 ,  C07C317/22 ,  C07C323/18 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/14 ,  C07C2601/16 ,  C07D209/12 ,  C07D213/64 ,  C07D231/12 ,  C07D307/80 ,  C07D317/54 ,  C07D333/56 ,  C07H15/203 ,  C07H17/00 ,  C07H17/02

    Abstract: A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, e.g., insulin dependent diabetes mellitus (type 1 diabetes) or noninsulin-dependent diabetes mellitus (type 2 diabetes), complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): (wherein A is —O—, —CH2—, or —NH—; n is an integer selected between 0 and 1; R6 and R7 each independently is hydrogen or C1-6 alkyl; m is an integer selected among 1-3; Q is selected among the following formulae Q1 to Q5; Ar1 is optionally substituted arylene or optionally substituted heteroarylene, provided that the heteroarylene may be bonded to an aromatic carbocycle or aromatic heterocycle to form a fused ring; and Ar2 is optionally substituted aryl or optionally substituted heteroaryl), a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, or the like each containing the compound.

    Abstract translation: 具有降低血糖水平并且具有药物所需的优选性能的持久性药物活性，代谢稳定性和安全性的环己烷衍生物; 以及用于预防或治疗高血糖疾病（例如糖尿病，例如胰岛素依赖性糖尿病（1型糖尿病）或非胰岛素依赖性糖尿病（2型糖尿病）），糖尿病并发症和肥胖症的药物组合物 。 该衍生物是由式（I）表示的化合物：其中A是-O-，-CH2-或-NH-; n是选自0和1之间的整数; R6和R7各自独立地是氢或C1- 6烷基; m是选自1-3中的整数; Q选自下式Q1至Q5; Ar1​​是任选取代的亚芳基或任选取代的亚杂芳基，条件是杂亚芳基可以键合到芳族碳环或芳族杂环以形成 稠合环; Ar 2是任选取代的芳基或任选取代的杂芳基），化合物的前药或其药学上可接受的盐。 还提供含有化合物的药物，药物组合物等。

    Novel Glucitol Derivative, Prodrug Thereof And Salt Thereof, And Therapeutic Agent Containing The Same For Diabetes
    8.
    发明申请
    Novel Glucitol Derivative, Prodrug Thereof And Salt Thereof, And Therapeutic Agent Containing The Same For Diabetes 失效
    新型葡萄糖醇衍生物，其药物及其盐，以及含有糖尿病的治疗剂

    公开(公告)号：US20080319047A1

    公开(公告)日：2008-12-25

    申请号：US11658765

    申请日：2005-07-27

    Applicant: Hiroharu Matsuoka ,  Tsutomu Sato ,  Masahiro Nishimoto ,  Yasuharu Kato ,  Masahiro Sakaitani ,  Sang-Hak Lee

    Inventor： Hiroharu Matsuoka ,  Tsutomu Sato ,  Masahiro Nishimoto ,  Yasuharu Kato ,  Masahiro Sakaitani ,  Sang-Hak Lee

    IPC: C07D409/10 ,  A61K31/381 ,  A61P3/10

    CPC classification number: C07D409/10

    Abstract: The invention provides a glucitol derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): wherein m is an integer selected among 1-3; R1 to R4 each independently is optionally substituted alkyl, etc.; Ar1 is optionally substituted naphthyl; and A is optionally substituted heteroaryl, a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, and the like each containing the compound.

    Abstract translation: 本发明提供了具有降低血糖水平并且具有药物所需的优选性能如持久药物活性的功能的葡糖醇衍生物; 以及用于预防或治疗高血糖疾病如糖尿病，糖尿病并发症和肥胖症的药物组合物。 该衍生物是由式（I）表示的化合物：其中m是选自1-3的整数; R1至R4各自独立地为任选取代的烷基等; Ar1是任选取代的萘基; 和A是任选取代的杂芳基，该化合物的前药或其药学上可接受的盐。 还提供了含有化合物的药物，药物组合物等。

    Compounds with hydroxycarbonyl-halogenoalkyl side chain
    9.
    发明授权
    Compounds with hydroxycarbonyl-halogenoalkyl side chain 失效
    具有羟基羰基 - 卤代烷基侧链的化合物

    公开(公告)号：US06737417B2

    公开(公告)日：2004-05-18

    申请号：US10149752

    申请日：2002-06-13

    Applicant: JaeChon Jo ,  HeeAn Kwon ,  HyunSuk Lim ,  JaeYoung Choi ,  Kazumi Morikawa ,  Yoshitake Kanbe ,  Masahiro Nishimoto ,  MyungHwa Kim ,  Yoshikazu Nishimura

    Inventor： JaeChon Jo ,  HeeAn Kwon ,  HyunSuk Lim ,  JaeYoung Choi ,  Kazumi Morikawa ,  Yoshitake Kanbe ,  Masahiro Nishimoto ,  MyungHwa Kim ,  Yoshikazu Nishimura

    IPC: C07J100

    CPC classification number: C07C59/64 ,  C07C51/38 ,  C07C59/54 ,  C07C59/56

    Abstract: The present invention provides a compound consisting of a moiety and a group chemically bonded to said moiety, wherein said moiety contains a compound having low activity following oral administration or its parent scaffold and said group has the following general formula (1): in which R1 represents a hydrogen atom, etc., R2 represents a C1-C7 halogenoalkyl group, etc., m represents an integer of 2 to 14, and n represents an integer of 2 to 7, or enantiomers of the compound, or hydrates or pharmaceutically acceptable salts of the compound or enantiomers thereof. The above compound is advantageous in pharmaceutical use because the group of general formula (1) allows compounds such as anti-estrogenic ones to show a significantly increased activity following oral administration when attached to the parent scaffolds of the compounds.

    Abstract translation: 本发明提供由部分和化学键合到所述部分的基团组成的化合物，其中所述部分含有口服后具有低活性的化合物或其母体支架，并且所述基团具有以下通式（1）：其中R 1表示 氢原子等，R2表示C1-C7卤代烷基等，m表示2〜14的整数，n表示2〜7的整数，或该化合物的对映异构体或其水合物或药学上可接受的盐 其化合物或其对映异构体。 上述化合物在药物用途中是有利的，因为通式（1）的基团允许化合物如抗雌激素的化合物在连接到化合物的母体支架上时在口服给药后显示出显着增加的活性。

    METHOD OF MANUFACTURING THIN-FILM SOLAR CELL MODULE
    10.
    发明申请
    METHOD OF MANUFACTURING THIN-FILM SOLAR CELL MODULE 审中-公开
    制造薄膜太阳能电池模块的方法

    公开(公告)号：US20120291866A1

    公开(公告)日：2012-11-22

    申请号：US13574125

    申请日：2011-02-07

    Applicant: Masahiro Nishimoto ,  Toshiharu Uchimi

    Inventor： Masahiro Nishimoto ,  Toshiharu Uchimi

    IPC: H01L31/0224 ,  H01L31/18

    CPC classification number: B32B37/1009 ,  B32B2305/34 ,  B32B2457/12 ,  H01L31/046 ,  H01L31/048 ,  H01L31/0481 ,  H01L31/0512 ,  Y02E10/50

    Abstract: A solar cell module is manufactured by resin-sealing a solar cell having a surface electrode to which a tab wire is connected, a tab wire is connected to the surface electrode and the solar cell is sealed with a sealing resin at a relative low temperature during the resin sealing step. For such purposes, a thin-film solar cell having a surface electrode to which a tab wire is connected is resin-sealed with a conductive adhesive film by using a decompression laminator, whereby the thin-film solar cell module is manufactured. A decompression laminator having a first chamber and a second chamber partitioned by a flexible sheet is used. Each chamber is capable of independent internal pressure adjustment. The second chamber includes a heating stage capable of heating. A resin mutually compatible with the thermoplastic resin constituting the conductive adhesive film is used as the sealing resin.

    Abstract translation: 太阳能电池模块通过树脂密封具有连接有突片线的表面电极的太阳能电池来制造，突片线连接到表面电极，并且太阳能电池在相对低的温度下用密封树脂密封 树脂密封步骤。 为了这样的目的，通过使用减压层压机，用导电性粘合剂膜将具有连接有突片线的表面电极的薄膜太阳能电池树脂密封，从而制造薄膜太阳能电池模块。 使用具有由柔性片分隔开的第一室和第二室的减压层压机。 每个室都能独立进行内部压力调节。 第二室包括能够加热的加热台。 使用与构成导电性粘合膜的热塑性树脂相溶的树脂作为密封树脂。

Patent Agency Ranking